Ipsen S.A. (IPSEY) Q2 2026 Earnings Call Transcript

The first half of 2026 was marked by excellent financials and progress on our strategy to accelerate growth of key medicines and expand the pipeline. We posted strong numbers with total sales growth at 23.5% at constant exchange rates and a 38.6% core operating margin. The late-stage pipeline is delivering with three positive Phase III readouts and three late-stage